Armanino Foods Files for 15-Day Extension for OTCQX 2024 Annual Financial Disclosure
PLEASANTON, Calif., April 01, 2025--(BUSINESS WIRE)--Armanino Foods of Distinction, Inc. (OTCQX: AMNF) announced today that it has filed an automatic 15-day extension with OTC Markets for its 2024 Annual Financial Disclosure.
The Company recently uplisted to the OTCQX Best Market in 2024, and the additional accounting and disclosure requirements have placed an added burden on the Company's internal accounting staff. Compounding the burden was the departure of the Company's CEO in January, which resulted in the Company's CFO stepping in as Acting CEO.
"This year also marks the first audit with a new independent auditing firm. While our previous auditors have continued to assist us through this transition, we are not yet at the finish line in completing the year-end audit," said Douglas Nichols, Chairman of the Board.
Nichols continued, "Management and staff are working diligently to complete the audit and file within the 15-day extension period. Of course, the final timeline also depends on the completion of our auditors' procedures, and we expect more clarity on that soon."
Despite these temporary delays in the audit process, Armanino's operations remain strong. For Q1 2025, the Company anticipates reporting another quarter of record sales and net income.
"We thank our shareholders for their ongoing trust and patience as we work through these reporting requirements. We remain committed to full transparency and to upholding the high standards that have defined Armanino for decades," Mr. Nichols added.
Armanino Foods of Distinction, Inc. is an international food company that manufactures and markets frozen Italian specialty food items to the foodservice, retail, and industrial markets. In addition to a classic Basil Pesto, Armanino offers other flavors and sauces including Cilantro, Dried Tomato & Garlic, Roasted Red Bell Pepper, Southwest Chipotle, Artichoke, Roasted Garlic, Light Basil Pesto, Chimichurri, Harissa, Bolognese, and Alfredo. Armanino's organic line includes classic Basil Pesto. Finally, Armanino Foods also offers cheese shakers, frozen pastas, and meatballs.
Cautionary Statements Regarding Forward-Looking Information
Statements in this news release regarding our expectations and beliefs about our future financial performance and trends in our markets are "forward-looking statements" as defined in the Private Securities Litigations Reform Act of 1995. Forward-looking statements often include the words "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may."
The forward-looking statements in this news release regarding our future financial performance are based on current information and because our business is subject to several risks and uncertainties, actual operating results in the future may differ significantly from the future financial performance expected at the current time. Those risks and uncertainties may include, among others: economic factors affecting consumer confidence and discretionary spending and reducing the consumption of food prepared away from home; the extent and duration of the negative impact of the COVID-19 pandemic and its consequences on the Company; cost inflation/deflation and commodity volatility; competition; reliance on third party suppliers and interruption of product supply or increases in product costs; changes in the Company's relationships with customers and group purchasing organizations; the Company's ability to increase or maintain the highest margin portions of the Company's business; achievement of expected benefits from cost savings initiatives; increases in fuel costs; changes in consumer eating habits; cost and pricing structures and other governmental regulation, including actions taken by national, state and local governments to contain and/or respond to the COVID-19 pandemic and its consequences; product recalls and product liability claims; and our reputation in the industry. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on information and estimates available to the Company at this time. We undertake no obligation to update or revise any forward-looking statements, except as may be required by law.
The best source of information on the company is the OTC Markets website (http://www.otcmarkets.com/stock/AMNF/company-info).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331684870/en/
Contacts
For further information, please contact:Edgar EstoninaCFO(510) 441-9300amnf@armaninofoods.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business of Fashion
11 minutes ago
- Business of Fashion
The Attico Opens First Store, in Ibiza
Italian fashion label The Attico has opened its first standalone boutique in Ibiza. Located in a newly developed area of the island, the store is the first in a series of concept-driven flagships. A second opening is set for Seoul later this year, with a Milan store also planned. Founded in 2016 by Gilda Ambrosio and Giorgia Tordini, The Attico started with a focused collection of robe-inspired silhouettes. Nearly a decade later, the brand offers a full lifestyle range including ready-to-wear, swimwear and accessories — all made in Italy, aside from intricate embroidery, which is crafted in India. (Courtesy) Each of the planned stores will be inspired by different rooms of an imagined apartment — an approach that mirrors the brand's long-standing interplay between fashion and interiors. The Ibiza store will be a bathroom, complete with a functioning bathtub and vintage vanity details. 'Ibiza is our second home,' Tordini said. 'This space makes our world tangible for the first time — it's an extension of our aesthetic and the women we speak to.' The boutique also signifies a gradual move into direct-to-consumer retail. The Attico currently sells through its own e-commerce site and a wholesale network of over 270 global stockists. Backed since 2018 by Archive, the investment vehicle founded by Moncler executive Remo Ruffini, The Attico has been quietly building infrastructure, expanding its internal team to 50 people. 'We've chosen to grow slowly and deliberately,' said Tordini. 'We could have sold much more, but we've always favoured a scarcity strategy to protect the brand's long-term value.' (Courtesy) As the brand prepares for its third official runway show this September during Milan Fashion Week, it continues to balance its Italian roots with global aspirations. 'The Attico woman is multifaceted — unapologetic, style-driven, with a global outlook,' said Tordini. 'This store is a milestone. It's the first time people can walk into our world, one room at a time.' Learn more: How Three Influencers Built Legitimate Fashion Brands The influencers behind Totême, Midnight 00 and The Attico have built respected multi-million-dollar businesses without resorting to blatant associations with their personal brands.
Yahoo
15 minutes ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
15 minutes ago
- Yahoo
DocuSign, Inc. (DOCU): A Bear Case Theory
We came across a bearish thesis on DocuSign, Inc. (DOCU) on Deep Value Returns' Substack. In this article, we will summarize the bears' thesis on DOCU. DocuSign, Inc. (DOCU)'s share was trading at $75.28 as of 6th June. DOCU's trailing and forward P/E were 14.31 and 20.07 respectively according to Yahoo Finance. A close-up of a laptop displaying loan documents, representing the company's residential mortgage guaranty insurance and mortgage loans. DocuSign (DOCU) saw its stock fall nearly 17% to around $77 following a disappointing fiscal 2026 outlook, which revised expected billings growth from 9% to 7% year-over-year. This was a significant setback for what had been a slow turnaround story, with billings being a key leading indicator of future revenue. The updated guidance casts doubt on the company's ability to reaccelerate growth, suggesting revenue may trend from 8% to as low as 5% y/y through the remainder of the year. Compounding concerns, DocuSign's free cash flow margins—a core pillar of the bull thesis—fell to 29.8% in Q1 from 32.7% a year earlier, prompting a downward revision of full-year margin expectations from 33% to 31%. While DocuSign still boasts a strong balance sheet with no debt and roughly $950 million in cash (about 6% of its market cap), the business is now expected to generate just $985 million in free cash flow, implying a 16x forward multiple for a company facing marginal growth. This valuation is no longer attractive in light of eroding operating leverage. The author, previously optimistic due to the company's margin potential and balance sheet strength, now views the risk/reward as balanced at best. With both billings and free cash flow coming in below even conservative expectations, the original thesis has broken down. As such, the author's position has been closed, with capital redirected toward opportunities offering stronger growth visibility and cleaner execution setups. This candid reassessment reflects a disciplined exit rather than emotional capitulation. Previously, we summarized a standout on Super Micro Computer by the same author, emphasizing its strategic alignment with AI infrastructure demand, scalable custom server offerings, and attractive free cash flow valuation, arguing that current headwinds are transitory and already priced in. DocuSign, Inc. (DOCU) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held DOCU at the end of the first quarter which was 51 in the previous quarter. While we acknowledge the risk and potential of DOCU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
